The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects

References

• Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381.
   Google Scholar
• Lammert M, Friedman JM, Kluwe L, et al. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005 Jan;141(1):71–74.
   Google Scholar
• Gutmann DH, Parada LF, Silva AJ, et al. Neurofibromatosis type 1: modeling CNS dysfunction. J Neuroscience. 2012 Oct 10;32(41):14087–14093.
   Google Scholar
• Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004 Apr;17(2):101–105.
   Google Scholar
• Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007 Feb;44(2):81–88.
   Google Scholar
• Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. ‎Am J Hum Genet. 2001 May;68(5):1110–1118.
   Google Scholar
• Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986 May 15;57(10):2006–2021.
   Google Scholar
• Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002 May;39(5):311–314.
   Google Scholar
• Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.
   Google Scholar
• Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005 Jul 26;65(2):205–211.
   Google Scholar
• De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003 May;72(5):1288–1292.
   Google Scholar
• Hattori S, Maekawa M, Nakamura S. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21. Oncogene. 1992 Mar;7(3):481–485.
   Google Scholar
• Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990 Nov 16;63(4):835–841.
   Google Scholar
• Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015 May;15(5):290–301.
   Google Scholar
• DeFazio MV, Ter Louw RP, Attinger CE, et al. Management of advanced plexiform neurofibromatosis of the foot presenting with skeletal deformation and intractable pain: an indication for proximal amputation. Foot. 2015 Mar;25(1):30–35.
   Google Scholar
• Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012 Mar;160(3):461–467.
   Google Scholar
• Reuss DE, Habel A, Hagenlocher C, et al. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathol. 2014 Apr;127(4):565–572.
   Google Scholar
• Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/– and c-kit-dependent bone marrow. Cell. 2008 Oct 31;135(3):437–448.
   Google Scholar
• Zheng H, Chang L, Patel N, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell. 2008 Feb;13(2):117–128.
   Google Scholar
• Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002 May 03;296(5569):920–922.
   Google Scholar
• Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999 Dec 10;286(5447):2172–2176.
   Google Scholar
• Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 1994 Aug;10(4):250–255.
   Google Scholar
• Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002 Aug;61(8):702–709.
   Google Scholar
• De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014 Oct 09;514(7521):247–251.
   Google Scholar
• Zhang M, Wang Y, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014 Nov;46(11):1170–1172.
   Google Scholar
• Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014 Nov;46(11):1227–1232.
   Google Scholar
• Beert E, Brems H, Daniels B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011 Dec;50(12):1021–1032.
   Google Scholar
• Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016 Sep;29(9):1113.
   Google Scholar
• Rohrich M, Koelsche C, Schrimpf D, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016 Jun;131(6):877–887.
   Google Scholar
• Hirbe AC, Dahiya S, Friedmann-Morvinski D, et al. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. 2016 Feb 16;7:7403–7414.
   Google Scholar
• Hirota S, Nomura S, Asada H, et al. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med. 1993 Oct;117(10):996–999.
   Google Scholar
• Patmore DM, Welch S, Fulkerson PC, et al. In vivo regulation of TGF-beta by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res. 2012 Oct 15;72(20):5317–5327.
   Google Scholar
• Dang I, DeVries GH. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB. J Neurosci Res. 2005 Feb 01;79(3):318–328.
   Google Scholar
• Friedrich RE, Beer C, Glatzel M, et al. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1. Anticancer Res. 2015 Jan;35(1):137–144.
   Google Scholar
• Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013 Feb 28;152(5):1077–1090.
   Google Scholar
• Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-Oncology. 2008 Aug;10(4):593–598.
   Google Scholar
• Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007 Feb 27;68(9):643–647.
   Google Scholar
• Nguyen R, Dombi E, Widemann BC, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012 Oct 04;7:75.
   Google Scholar
• Higham C, Bhaumik S, Dombi E, et al. Atypical neurofibromas in neurofibromatosis 1 (NF1): clinical, imaging and pathologic characteristics. ASCO Annual Meeting; 2016 June 3-7; Chicago, IL.
   Google Scholar
• Akshintala S, Bhaumik S, Venkatesan A, et al. Imaging and clinical features of lesions suspicious for malignant transformation in neurofibromatosis type 1 (NF1) associated Plexiform Neurofibromas (PNs)). Radiological Society of North America 2014 Prod Scientific Assembly and Annual Meeting; 2014 May 30-June 3; Chicago, IL.
   Google Scholar
• Sbidian E, Wolkenstein P, Valeyrie-Allanore L, et al. NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Dermatol. 2010 Sep;130(9):2173–2178.
   Google Scholar
• Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013 Jan;38(1):e19–e25.
   Google Scholar
• Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008 Feb;19(2):390–394.
   Google Scholar
• Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone. 4th ed. IARC; Lyon, France: World Health Organization/International Agency for Research on Cancer. 2013.
   Google Scholar
• Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012 Mar;123(3):295–319.
   Google Scholar
• Pekmezci M, Reuss DE, Hirbe AC, et al. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol. 2015 Feb;28(2):187–200.
   Google Scholar
• Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15;91(10):1914–1926.
   Google Scholar
• Gall Troselj K, Novak Kujundzic R, Ugarkovic D. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics. 2016;8:55.
   Google Scholar
• Asano N, Yoshida A, Ichikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology. 2017 Feb;70(3):385–393.
   Google Scholar
• Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016 Jan;29(1):4–13.
   Google Scholar
• Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550–2560.
   Google Scholar
• Hruban RH, Shiu MH, Senie RT, et al. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 1990 Sep 15;66(6):1253–1265.
   Google Scholar
• Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013 Jan;118(1):142–148.
   Google Scholar
• Widemann Brigette C, Reinke DK, Helman LJ, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). J Clinical Oncology. 2013;suppl; abstr 10522.
   Google Scholar
• Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002 Mar 1;62(5):1573–1577.
   Google Scholar
• Kaushal A, Citrin D. The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 2008;88(3):629–646, viii. Jun.
   Google Scholar
• Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clinical Oncology. 1998 Jan;16(1):197–203.
   Google Scholar
• Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clinical Oncology. 2006 Jun 01;24(16):2570–2575.
   Google Scholar
• Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006 Apr;43(4):289–294.
   Google Scholar
• Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clinical Oncology. 2005 Nov 20;23(33):8422–8430.
   Google Scholar
• Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer. 2011 Mar;47(5):724–731.
   Google Scholar
• Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group Study. Ann Oncol. 2011 Jan;22(1):207–214.
   Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clinical Oncology. 2001 Mar 1;19(5):1238–1247.
   Google Scholar
• Schenone AD, Luo J, Montgomery L, et al. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. Cancer Med. 2014 Jun;3(3):603–612.
   Google Scholar
• Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clinical Oncology. 1985 Jun;3(6):818–826.
   Google Scholar
• Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer. 2003 Apr;4(Suppl 1):S26–33.
   Google Scholar
• Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228.
   Google Scholar
• Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clinical Oncology. 2000 May;18(10):2081–2086.
   Google Scholar
• Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1: p53mouse tumor model. Cancer Res. 2002 Aug 1;62(15):4507–4513.
   Google Scholar
• Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol (Meeting Abstracts). 2006;24(18_suppl):9518.
   Google Scholar
• Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clinical Oncology. 2009 Jul 01;27(19):3133–3140.
   Google Scholar
• Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clinical Oncology. 2009 Jul 01;27(19):3148–3153.
   Google Scholar
• Schuetze S, Wathen K, Choy E, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J Clin Oncol (Meeting Abstracts). 2010;28(15s):suppl;abstr 10009.
   Google Scholar
• Widemann BC, Meyer CF, Cote GM, et al. SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol (Meeting Abstracts). 2016;34:suppl; abstr 11053.
   Google Scholar
• Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011 Mar;6(1):17–27.
   Google Scholar